No consensus yet in Ethiopia's disputed dam ‘separate talks'    Upcoming significant pickup mergers, acquisitions likely due to COVID-19    Canada should focus on boosting the economy even as debt climbs -analysts    Egypt is attractive destination for portfolio investment: Citigroup    Citigroup continues investments in EMEA region's treasury, trade solutions    Algeria buries fighters whose skulls were in Paris museum    Real Madrid move closer to Spain La Liga title with 7th straight win    Sexual abuse in Egypt: social media lead the fight against repulsive phenomenon    German economy minister sees economic recovery starting October    Sissoko urges patience with Spurs' record signing Ndombele    Trump repeats vow to defeat 'radical left' in 4 July speech    Egypt's Court of Cassation upholds prison sentences for 56 convicted in 2013 Nahda dispersal case    Iran records highest daily death toll from COVID-19    WHO reports new coronavirus cases reach all-time high    Travel quarantine rules relaxed for top sports events in England    Tokyo governor wins 2nd term, buoyed by handling of virus    Italy-based asset manager, Azimut, launches its Egypt-focused equity fund    UK's CDC provides CIB with USD 100 mn in tier II capital agreement    MENA construction output to decline; slow 2021 recovery expected    TikTok distances from Beijing in responce to India app ban    Iconic actress Ragaa El-Gedawy passes away at 81 from COVID-19    Egypt records 1,324 new coronavirus cases on Saturday – health ministry    Boris Johnson likely to start phasing out Huawei's 5G role soon    Rocket fired towards Baghdad Green Zone, child injured: Military, police source    Jets hit Libya's al-Watiya airbase where Turkey may build base, sources say    Crunch, crunch: Africa's locust outbreak is far from over    Egyptian veteran actress Ragaa El-Gedawy dies from coronavirus at 81    Egypt condemns Houthi attacks on Saudi territories    NCW files complaint with Public Prosecutor over harassment, rape allegations circulated online    Egypt says no breakthrough reached on second day of AU-sponsored GERD talks    UAE adopts new government structure, full announcement to come on Sunday    Ministry of Culture announces schedule for resumed theatrical, musical activities    Virtual talks on Ethiopia's disputed dam resume amid consensus hopes    Egypt to hold Senate elections on 11-12 August: NEC    5 killed, 10 injured in bomb attack in southwest Somalia    Egypt reopens 5 museums, 8 archaeological sites and operates 171 international, domestic flights    GERD talks between Egypt, Ethiopia and Sudan resume on Friday    Rudolfo Anaya, 'godfather' of Chicano literature, dies at 82    Egypt's Zamalek to continue training Thursday, but domestic league participation unclear    Liverpool boss Klopp happy with African Nations Cup postponement    Egypt's cultural activities to resume mid-July    Federation of Egyptian Banks denies funding GERD: eletreby    Saudi development authority starts executing phase I of giant cultural project    11 coronavirus cases detected at Egyptian Premier League clubs – EFA    Egypt to host World Handball Championship on time despite COVID-19: EHF President    Liverpool's Egyptian winger Salah fit for Crystal Palace clash – coach Klopp    Egypt's parliament Oks amendments to House law amid differences over election    CAF draws timeline for resumed continental championships amid COVID-19    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

Hope in the fight against Covid-19
Published in Ahram Online on 14 - 04 - 2020

On 7 April, Japanese top diplomat Toshimitsu Motegi declared that his country would allow 20 other countries to test Avigan, a drug for influenza that has helped patients in China to recover from the Covid-19 coronavirus.
Its usefulness has yet to be confirmed in clinical tests, but Japan seeks to “work with interested countries to expand clinical research on Avigan internationally,” Motegi said, in order to find out whether it could be effective as a therapy against the coronavirus.
Among the countries involved in the Avigan tests are Bulgaria, the Czech Republic, Indonesia, Iran, Myanmar, Saudi Arabia and Turkey. Thirty more countries, according to Motegi, are also interested in trying it.
The Japanese Fujifilm Corporation, Avigan's producer, issued a statement saying that about 50 coronavirus patients in the United States would be given the drug as part of a joint project between the company and Brigham and Women's Hospital in Boston, Massachusetts General Hospital and the University of Massachusetts Medical School.
Egypt has also expressed interest in the drug. “We are on our way to the manufacturing stage... after we contact the Chinese side responsible for producing the pharmaceutical ingredients ... and the approval of the Japanese company… to get enough of the ingredients in order to manufacture the drug,” Higher Education and Scientific Research Minister Khaled Abdel-Ghaffar said last week.
Avigan earned approval for manufacture in Japan in 2014 as an antiviral influenza drug. Fujifilm said that it is to “be considered for use only when there is an outbreak of novel or re-emerging influenza virus infections in which other influenza antiviral drugs are either not effective or insufficiently effective. The Japanese government has decided to use the drug as a countermeasure against such influenza viruses.”
The company said that Avigan was a promising therapy for the novel coronavirus because it “has a mechanism of action for selectively inhibiting RNA polymerase involved in influenza viral replication.” Covid-19 “is classified in the same type of single-stranded RNA virus as influenza, and its [Avigan's] clinical application to treat Covid-19 is now under study,” Fujifilm said in a press statement on 31 March.
In March, the Chinese medical authorities praised Avigan for having “a high degree of safety and [being] clearly effective in the treatment” of coronavirus. It had been used on 340 patients in Wuhan and Shenzan, and patients who had tested positive for coronavirus recovered almost four days after taking the drug, they said.
Those who did not, according to Japan's NHK national broadcaster, felt better after roughly 11 days. A source at the Japanese Health Ministry told the Mainichi Shimbun, a Japanese newspaper, that Avigan “doesn't seem to work that well when the virus has already multiplied,” suggesting that the drug should be used early in the infection.
Medical researchers, pharmaceutical companies and world leaders have repeatedly emphasised that a vaccine for coronavirus will not be ready before a year from now. A reliable therapy is thus greatly needed.
According to World Health Organisation (WHO) figures, more than two million people around the world tested positive for coronavirus.
*A version of this article appears in print in the 16 April, 2020 edition of Al-Ahram Weekly

Clic here to read the story from its source.